Prostate Medication, Metabolism and Gut Microbiota

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2026

Conditions
Prostatic HyperplasiaProstate Cancer
Interventions
DRUG

Prostate hyperplasia medication

The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.

DRUG

LhRH-antagonist

The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.

Trial Locations (2)

20100

RECRUITING

Turku University Hospital, Turku

RECRUITING

University of Turku, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV